Jun Li, et al. - Researchers designed this network meta-analysis(NMA) to gather all efficacy evidence, enabling a comparison of all single-agent methotrexate(MTX)-based or actinomycin-d (Act-D)-based regimens in low-risk gestational trophoblastic neoplasia (LRGTN). As per findings, 5-day intravenous Act-D (5d-IV Act-D) and pulsed intravenous Act-D (pulsed IV Act-D) appeared to be the best treatment options in LRGTN. Pulsed Act-D had the least toxic in nausea and vomiting. They observed grade 3/4 adverse events (AEs) more frequently in 5d-IM MTX, followed by 5d-IV Act-D.